Severe pemphigus vulgaris: Successful combination therapy of plasmapheresis followed by intravenous high-dose immunoglobulin to prevent rebound increase in pathogenic IgG

European Journal of Dermatology

Volumn 18, Issue 5, 2008, Pages 557-560

  Aoyama, Yumi ^a   Nagasawa, Chikako ^a   Nagai, Miki ^a   Kitajima, Yasuo ^a  

^a GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Double filtration plasmapheresis; High dose IVIg; Pemphigus

Indexed keywords

AZATHIOPRINE; DESMOGLEIN 1 ANTIBODY; DESMOGLEIN 3 ANTIBODY; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE;

ACANTHOLYSIS; ADULT; ANTIBODY TITER; ARTICLE; BACTERIUM CULTURE; BLISTER; CASE REPORT; CLINICAL FEATURE; DIZZINESS; DOSE RESPONSE; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG PULSE THERAPY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; EROSION; HISTOPATHOLOGY; HUMAN; IMMUNOFLUORESCENCE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEPOSITION; LOW DRUG DOSE; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; PEMPHIGUS VULGARIS; PLASMAPHERESIS; REBOUND; RECURRENCE RISK;

COMBINED MODALITY THERAPY; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PEMPHIGUS; PLASMAPHERESIS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 52649088903     PISSN: 11671122     EISSN: None     Source Type: Journal    
DOI: 10.1684/ejd.2008.0471     Document Type: Article

References (18)

1. Mazzi G, Raineri A, Zanolli FA, Da Ponte C, De Roia D, Santarossa L, Guerra R, Orazi BM. Plasmapheresis therapy in pemphigus vulgaris and bullous pemphigoid. Transfus Apher Apher Sci 2003; 28: 13-8.
2. Bystryn JC, Rudolph JL. Pemphigus. Lancet 2005; 366: 61-73.
3. Bystryn JC, Steinman NM. The adjuvant therapy of pemphigus. An update. Arch Dermatol 1996; 132: 203-12.
4. Bystryn JC, Rudolph A. IVI g Treatment of pemphigus: how it works and how to use it. J Invest Dermatol 2005; 125: 1093-8.
5. Eyre RW, Stanley JR. Identification of pemiphigus vulgaris antigen extracted from normal human epidermis anc comparison with pemphigus foliaceus antigen. J Clin Invest 1988; 81: 807-12.
6. Hashimoto T, Ogawa MM, Konohana A, Nishikawa T. Detection of pemphigus vulgaris and pemphigus foliaceus antigens by immunoblot analysis using different antigen sources. J Invest Dermatol 1990; 94: 327-31.
7. Koulu L, Kusumi A, Steinberg MS, Klaus-Kovtun V, Stanley JR. Human autoantibodies against a desmosomal core protein in pemphigus foliaceus. J Exp Med 1984; 160: 1509-18.
8. Kowalczyk AP, Anderson JE, Borgwardt JE, Hashimoto T, Stanley JR, Green KJ. Pemphigus sera recognize conformationally sensitive epitopes in the amino-terminal region of desmoglein-1. J Invest Dermatol 1995; 105: 147-52.
9. Amagai M. Autoimmunity against desmosomal cadherins in pemphigus. J Dermatol Sci 1999; 20: 92-102.
10. Kitajima Y. Current and prospective understanding of clinical classification, pathomechanisms and therapy in pemphigus. Arch Dermatol Res 2003; 295(Suppl 1): S17-S23.
11. Kottke MD, Delva E, Kowalczyk AP. The desmosome: cell science lessons from human diseases. J Cell Sci 2006; 119: 797-806.
12. Anhalt GJ, Labib RS, Voorhees JJ, Beals TF, Diaz LA. Induction of pemphiqus in neonatal mice by passive transfer of IgG from patients with the disease. N Engl J Med 1982; 306: 1189-96.
13. Amagai R, Karpati S, Prussick R, Klaus-Kovtun V, Stanley JR. Autoantibodies against the amino-terminal cadherin-like binding domain of pemphigus vulgaris antigen are pathogenic. J Clin Invest 1992; 90: 919-26.
14. Amagai M, Hashimoto T, Shimizu N, Nishikawa T. Absorption of pathogenic autoantibodies by the extracellular domain of pemphigus vulgaris antigen (Dsg3) produced by baculovirus. J Clin Invest 1994; 94: 59-67.
15. Bystryn JC, Jiao D, Natow S. Treatment of pemphigus with intravenous immunoglobulin. J Am Acad Dermatol 2002; 47: 358-63.
16. Sami N, Qureshi A, Ruocco E, Ahmed AR. Corticosteroid-sparing effect of intravenous immunoglobulin therapy in patients with pemphigus vulgaris. Arch Dermatol 2002; 138: 1158-62.
17. Gurcan H, Ahmed AR. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid. Ann Pharmacother 2007; 41: 1604-10.
18. Tan-Lim R, Bystryn JC. Effect of plasmapheresis therapy on circulating levels of pemphigus antibodies. J Am Acad Dermatol 1990; 22: 35-40.